I am familiar with this issue and have spoken to the Minister for Health on it. The Deputy will be aware of the framework governing this area which can be quite frustrating for the political system. However, it was designed to try to get as objective an assessment as possible. We had similar debates on Orkambi. Parents of children with cystic fibrosis say that Orkambi has had a huge impact and it is my instinct that the same would apply to Kaftrio. The company also needs to engage here. Between the agency and the company, I would like to think the interests of these 35 children would be prioritised to enable them to have access to this drug.

See this speech in context